Antegenes is a health technology company specializing in personalized cancer prevention through advanced genetic testing. Their primary innovation is the Polygenic Risk Score (PRS), which aggregates data from numerous genetic variants to assess an individual's risk of developing various cancers, including breast, prostate, colorectal, and melanoma. By integrating this genetic information with demographic factors such as age, gender, and ethnicity, Antegenes provides tailored medical advice aimed at early detection and prevention strategies. Their tests have been validated using data from reputable biobanks, ensuring a high level of accuracy in risk assessment.

The company emphasizes the importance of a comprehensive approach to cancer prevention, which can potentially reduce mortality rates by 30-40%. Antegenes collaborates with leading oncologists and medical geneticists to develop their services, ensuring that the recommendations provided are clinically relevant and evidence-based. Their commitment to precision medicine is further underscored by their ISO 13485 certification, which reflects their adherence to quality management standards in the medical device industry. Through their innovative testing solutions, Antegenes aims to empower individuals to take proactive steps in managing their health and mitigating cancer risks.

Estonia

Antegenes is a healthcare technology company developing and implementing innovative genetic tests based on polygenic risk score technology to enable personalised prevention of common cancers.

Antegenes

Company Details